Navigation Links
BioMarin Announces Third Quarter 2010 Financial Results
Date:10/28/2010

ensation expense8.910.025.727.734.537.0Upfront license fees

(1)--8.8-8.8-Impairment charges

(2)--5.9-5.9-Net gain on the sale of equity investments--(1.6)(1.0)(1.6)(1.0)Acquisition expenses

(3)1.81.8-2.0Tax benefit

(4)-(223.1)(223.1)-(223.0)Income tax effect of Non-GAAP adjustments

(5)-0.3---Non-GAAP net income $

15.5$

6.0$

33.9$

23.4$

47.1$

28.0 to 33.0Notes: (1)  Represents upfront license payments related to our collaboration agreement with La Jolla Pharmaceutical Company in the first quarter of 2009.   (2)  Includes impairment losses on investments in Summit plc. and La Jolla Pharmaceutical Company recognized during the first quarter of 2009.(3)  Represents transactions costs associated with the acquisition of ZyStor Therapeutics Inc., during the third quarter of 2010.   (4)  Represents the release of the Company's income tax valuation allowance during the third quarter of 2010.(5)  Represents the tax effect of the adjustments.   BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan, Aldurazyme and Firdapse and development of its pipeline.  By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future.  Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes.

Diluted Earnings Per Share Calculation For the third quarter of 2010, the nine months ended September 30, 2010 and the full year forecast for the year ending 20
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Host a Research and Development Day on October 19th
2. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
3. BioMarin to Present at the UBS Global Life Sciences Conference
4. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
5. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
6. BioMarin Acquires ZyStor Therapeutics, Inc.
7. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
8. BioMarin to Acquire LEAD Therapeutics
9. BioMarin to Present at the Credit Suisse Healthcare Conference
10. BioMarin Announces Third Quarter 2009 Financial Results
11. BioMarin to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... and LONDON , August 26, 2014 ... FDNA Inc. ( http://www.fdna.com ) and London Medical Databases ... partnered to offer, for the first time, online access ... FDNA, developer of the Facial Dysmorphology ... collection into Face2Gene [ TM ] , ...
(Date:8/26/2014)... SAN DIEGO , Aug. 26, 2014   ... M.D., has been named vice president, clinical development, and ... president, clinical operations. "As we advance ... we are expanding our clinical team with individuals who ... and commercialization activities," said Jamey Skillings , M.D., ...
(Date:8/26/2014)... , Aug. 26, 2014  Zimmer Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2014. The cash dividend of ... 31, 2014, to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
Breaking Medicine Technology:FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 2FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 3Tocagen Expands Clinical Development Team; 2Tocagen Expands Clinical Development Team; 3
... N.J., July 26, 2011 Watson Pharmaceuticals, Inc. ... definitive agreement to acquire a portfolio of generic ... result of the merger between Perrigo Company and ... including four FDA-approved products and two undisclosed development-stage ...
... N.J., July 26, 2011 The Board of Directors of ... a leading global medical technology company, today announced that, in ... A. Forlenza as Chief Executive Officer and President, effective October ... the Board at that time. Also effective October 1, current ...
Cached Medicine Technology:Watson Enters into Agreement to Acquire Products Related to Perrigo's Acquisition of Paddock Laboratories 2BD Board of Directors Elects Vincent A. Forlenza as Next Chief Executive Officer, Effective October 1, 2011 2BD Board of Directors Elects Vincent A. Forlenza as Next Chief Executive Officer, Effective October 1, 2011 3
(Date:8/27/2014)... Crossing, PA (PRWEB) August 27, 2014 Time ... successfully launched its first-ever golf event! , With 80-degree ... for the Time To Play Golf (TTPGolf) Inaugural Outing. Around ... August 4th event, staged at the beautiful Heron Glen Golf ... with a bang and everyone seemed to be having a ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 PCOS (Polycystic ... and puts them at risk for a number of ... widely known or well understood even within the medical ... excess body hair (hirsutism) and excess body fat around ... aware that their problems are caused by PCOS. , ...
(Date:8/27/2014)... The Connecticut Community for Addiction Recovery (CCAR) ... 2014, from 10:00 AM – 2:00 PM in Bushnell Park ... participants across the state to show their support for recovery ... state capitol. , Recovery Walks! is a celebration for the ... and other drugs as well as their families, friends, and ...
(Date:8/26/2014)... 2014 Recently, BambooIndustry.com, the popular online ... of bamboo floorings for the online market. ... flooring promotion. All the new items are offered at ... The special offer will end on September 10, 2014. ... floorings are provided with low shipping costs. The company ...
(Date:8/26/2014)... (PRWEB) August 27, 2014 In its ... offers treatment programs and believes that having family close ... big difference in whether or not the process is ... without medication. , “While many people need medication to ... withdrawal symptoms and fighting relapse triggers like anxiety and ...
Breaking Medicine News(10 mins):Health News:Recap: Time To Play Golf Inaugural Golf Outing 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 3Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 4Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 5Health News:The CT Community for Addiction Recovery to Proudly Host 15th Annual Recovery Walks! 2Health News:Discounted, High Quality Bamboo Floorings Provided Online By BambooIndustry.com 2Health News:Latest Best Drug Rehabilitation Blog Post Looks at 6 Ways to Beat Addiction with Medication 2Health News:Latest Best Drug Rehabilitation Blog Post Looks at 6 Ways to Beat Addiction with Medication 3
... the AIDS drug Retrovir (AZT). This generic drug// is manufactured ... be able to market this anti-retroviral drug in US, but ... it will be made available for purchase and use abroad ... emergency plan for AIDS relief was announced in 2003, by ...
... sectional study across Europe, researchers have reported// that there ... the parents and their socio-economic status with the condition ... carried across the countries of Denmark, Estonia, and Portugal, ... Journal (BMJ). ,Across Europe, children from poor families ...
... Gengraine Technologies (Avesthagen) of India is collaborating// with ... Developing Countries (IFU) of Germany for Osteoporosis research. ... euro. Avesthagen said “"The alliance will cover diagnosis, ... disorders.” The research studies related to menopause linked ...
... Technologists annual meeting in US// have warned the general people ... these are illnesses that can threaten the health of the ... ,The studies presented at the meeting said that often people ... illnesses. A healthy adult is less likely to contract a ...
... the research carried out so far into the effects// of ... a new phase III trial is scheduled to commence this ... escalated, causing soaring prices and reports of fake products entering ... been triggered by the publication of Shults’ earlier phase II ...
... (albumin is major part// the protein spectrum in the body) ... study. A simple, inexpensive test for urinary albumin may help ... deliver early. ,A study was released in the American ... Kidney Foundation) this month that suggests this test. "Research ...
Cached Medicine News:Health News:Education And Income Level May Not Guarantee Health 2Health News:Scientists Warn Against Food Borne Illnesses 2Health News:New Study to look at the Beneficial Effects of Coenzyme Q10 on Parkinson’s disease 2Health News:Premature Babies More Likely If Women Have Higher Protein Albumin In Urine 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 12.0 mm and length 18 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 12 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 11.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 9 mm....
Medicine Products: